Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study
This week, dosing was completed according to plan in the second clinical study with Immunose™ FLU, developed with the aim to become a modern and effective nasal influenza vaccine.- In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer. -The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision,